177 related articles for article (PubMed ID: 35782609)
21. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy.
Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707
[TBL] [Abstract][Full Text] [Related]
22. Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease.
Charkhand B; Scantlebury MH; Narita A; Zimran A; Al-Hertani W
Mol Genet Metab Rep; 2019 Sep; 20():100476. PubMed ID: 31467847
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris Feldman H; Ghosn M; Mehta A; Packman S; Lau H; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Foster MC; Gaemers SJM; Peterschmitt MJ
Am J Hematol; 2021 Sep; 96(9):1156-1165. PubMed ID: 34161616
[TBL] [Abstract][Full Text] [Related]
24. Profile of eliglustat tartrate in the management of Gaucher disease.
Sechi A; Dardis A; Bembi B
Ther Clin Risk Manag; 2016; 12():53-8. PubMed ID: 26811686
[TBL] [Abstract][Full Text] [Related]
25. Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1.
Peterschmitt MJ; Freisens S; Underhill LH; Foster MC; Lewis G; Gaemers SJM
Orphanet J Rare Dis; 2019 Jun; 14(1):128. PubMed ID: 31174576
[TBL] [Abstract][Full Text] [Related]
26. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
27. Patients with Gaucher disease display systemic oxidative stress dependent on therapy status.
Kartha RV; Terluk MR; Brown R; Travis A; Mishra UR; Rudser K; Lau H; Jarnes JR; Cloyd JC; Weinreb NJ
Mol Genet Metab Rep; 2020 Dec; 25():100667. PubMed ID: 33335836
[TBL] [Abstract][Full Text] [Related]
28. Large Mesenteric Gaucheroma Responds to Substrate Reduction Therapy: A New Management of Gaucheromas.
Yano S; Moseley K; Mahajan N; Warren M; Vachon L
J Pediatr Genet; 2022 Mar; 11(1):47-50. PubMed ID: 35186390
[TBL] [Abstract][Full Text] [Related]
29. Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat.
Harai N; Ichijo M; Uchinuma H; Hanihara M; Kawaguchi Y; Ichikawa D; Tsuchiya K
Intern Med; 2023 Oct; 62(20):3005-3011. PubMed ID: 36889706
[TBL] [Abstract][Full Text] [Related]
30. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
32. A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy.
Komada N; Fujiwara T; Yoshizumi H; Ida H; Shimoda K
Case Rep Gastroenterol; 2021; 15(3):838-845. PubMed ID: 34720832
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.
Schwartz IVD; Göker-Alpan Ö; Kishnani PS; Zimran A; Renault L; Panahloo Z; Deegan P;
Mol Genet Metab Rep; 2018 Mar; 14():73-79. PubMed ID: 29326879
[TBL] [Abstract][Full Text] [Related]
34. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
Cox TM; Drelichman G; Cravo R; Balwani M; Burrow TA; Martins AM; Lukina E; Rosenbloom B; Ross L; Angell J; Puga AC
Lancet; 2015 Jun; 385(9985):2355-62. PubMed ID: 25819691
[TBL] [Abstract][Full Text] [Related]
35. Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial.
Mistry PK; Lukina E; Ben Turkia H; Shankar SP; Baris H; Ghosn M; Mehta A; Packman S; Pastores G; Petakov M; Assouline S; Balwani M; Danda S; Hadjiev E; Ortega A; Gaemers SJM; Tayag R; Peterschmitt MJ
Am J Hematol; 2017 Nov; 92(11):1170-1176. PubMed ID: 28762527
[TBL] [Abstract][Full Text] [Related]
36. Long-Term Outcomes of Disease Modifying Therapies in Gaucher Disease.
Manisha R; Phadke SR
Indian J Pediatr; 2024 Feb; ():. PubMed ID: 38315376
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.
Deegan P; Lau H; Elstein D; Fernandez-Sasso D; Giraldo P; Hughes D; Zimran A; Istaiti M; Gadir N; Botha J; Revel-Vilk S;
J Clin Med; 2024 May; 13(10):. PubMed ID: 38792324
[No Abstract] [Full Text] [Related]
38. Eliglustat: A Review in Gaucher Disease Type 1.
Scott LJ
Drugs; 2015 Sep; 75(14):1669-78. PubMed ID: 26384672
[TBL] [Abstract][Full Text] [Related]
39. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N; Di Rocco M; Fraga C; Giraldo P; Hughes D; Lukina E; Maison-Blanche P; Merkel M; Niederau C; Plӧckinger U; Richter J; Stulnig TM; Vom Dahl S; Cox TM
Eur J Intern Med; 2017 Jan; 37():25-32. PubMed ID: 27522145
[TBL] [Abstract][Full Text] [Related]
40. Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study.
Camou F; Lagadec A; Coutinho A; Berger MG; Cador-Rousseau B; Gaches F; Belmatoug N
Mol Genet Metab; 2023 Nov; 140(3):107667. PubMed ID: 37597334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
